Androgen Receptor Antagonist ARN-509

Phase 2Small molecule

RRutgers, The State University of New Jersey

Androgen Receptor Antagonist ARN-509 is one of 25 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Stage II Prostate AdenocarcinomaActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Stage II Prostate AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Mekinist

Novartis

Preclinical

3 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Androgen Receptor Antagonist ARN-509

RRutgers, The State University of New Jersey

Phase 2

1 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Ifex

BBaxter Healthcare Corporation

Xylocaine

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Stage II Prostate Adenocarcinoma

NCT02949284

Clinical

Trials by Indication[1]

Stage II Prostate Adenocarcinoma1 trial

Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer

Active, not recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT02949284·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Androgen Receptor Antagonist ARN-509. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Androgen Receptor Antagonist ARN-509 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Androgen Receptor Antagonist ARN-509. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rutgers, The State University of New Jersey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRutgers, The State University of New Jersey

Androgen Receptor Antagonist ARN-509

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Stage II Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News